GGrantIndex
← Search

Gene Targeting & Transgenic Shared Resource

$83,379P30FY2019CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

The mission of the Gene Targeting and Transgenic Shared Resource (GeTT) is to ensure that Roswell Park CCSG members have access to state-of-the-art transgenic mouse technologies, methods and animal models. With the development of contemporary mammalian genome manipulation technologies, genetically engineered mice have become a source of new cancer models that have helped elucidate pathways contributing to tumor development and progression. GeTT has generated over 1,000 novel genetically engineered mouse lines for CCSG program members. The recent introduction of CRISPR/Cas9 genome editing technologies has drastically improved the efficiency of generating new mouse models, and enabled some critical new research by Roswell Park investigators that would not have been otherwise possible. In the reporting period (2013- 2017), the GeTT served a total of 47 Roswell users, of which 42 (89%) were CCSG members. Typically, GeTT charges its CCSG members ~one-third of what commercial companies would charge to create genetically engineered mice. The Resource Director and Co-Director provide guidance to investigators from the earliest planning stages of the project when constructs are designed to advanced stages of the project during phenotype analysis. Resource technicians perform the specialized ES cell and embryo manipulation methods to generate the genetically engineered mice. Projects requiring the development of transgenic mouse models are becoming increasingly relevant to validate findings from in vitro studies and from high-throughput clinical- based datasets. The Specific Aims of the GeTT are: 1) To ensure that Roswell Park CCSG members, have access to state-of-the-art transgenic methods, technologies, and mouse models; 2) To serve as a ?one-stop? Shared Resource for consultation, education, training and expert support related to genetic engineering of mouse models; 3) To work synergistically with other shared resources at Roswell Park to provide the optimized research environment for CCSG members. The GeTT has significant expertise in providing all the necessary technologies and services to achieve the objectives of the Aims. The GeTT future plan is to increase the number of CCSG members utilizing the GeTT by optimizing several new CRISPR-based genome-editing techniques. GeTT is currently developing new techniques such as Easi-CRISPR and GONAD (Gonadal oviductal transfer of Nucleic Acid Delivery). In addition GeTT has recently developed a service that offers mouse colony management to CCSG member labs who do not have previous experience in complex mouse breeding for cohort analysis.

View original record on NIH RePORTER →